Tag: PYC
Phylogica achieves milestone in drug study aimed at treating childhood blindness
Biotechnology company Phylogica (ASX: PYC) is one step closer to finding a treatment for the leading cause of childhood blindness, achieving a major milestone in its human ‘retina in a dish’ study.
...
Phylogica’s cell penetrating platform linked to effective administration of drugs for genetic eye disease
A drug delivery platform developed by biotechnology company Phylogica (ASX: PYC) has been shown to be the most effective method of administering anti-sense oligonucleotide (ASO) medications to patient...
Phylogica’s cell peptide delivery platform achieves early success in human cell studies for blinding eye diseases
Perth-based biotech company Phylogica (ASX: PYC) has reported positive early stage results from a pilot study of human cells using its proprietary drug delivery technology to create a treatment for bl...
Phylogica obtains successful time-course study results for flagship CPP platform
Biotechnology company Phylogica (ASX: PYC) has unveiled favourable lab results in relation to its time-course studies in animals, with superior performance to current benchmarks officially confirmed.
...
Phylogica reports positive peptide vaccine T-Cell expansion results in vivo
Perth-based biotechnology company Phylogica (ASX: PYC) has announced a successful round of in vivo results in the evaluation of its cell-penetrating peptide (CPP) vaccine program.
Peptides are pote...
Purposeful cell targeting delivers commercial spoils for Phylogica
Biotech company Phylogica (ASX: PYC) has announced it has developed a new recombination enzyme, Cre, thereby supplementing its ongoing research into a proprietary in vitro drug delivery platform.
P...
Phylogica’s peptide technology effective in development of cancer vaccine
Phylogica (ASX: PYC) has praised the effectiveness of its Functional Penetrating Peptide (FPP) technology to stimulate an immune response and extend cancer survival rates through recent testing on mic...
